TY - JOUR
T1 - Developing consensus on rare disease care pathways and ERN integration across Europe
T2 - insights from stakeholder workshops and a Delphi study
AU - Juozapavičiūtė-Dvinelė, Augutė
AU - Tsang-A-Sjoe, Michel W.P.
AU - B.ZiemeleBaibaJA JARDIN WP6 collaborators
AU - Auzenbaha, Madara
AU - Ažukaitis, Karolis
AU - Tumienė, Birutė
AU - Obšilová, Dagmar
AU - L'khssim, Ikram
AU - Osmanovic, Alma
AU - Philippe, Corcia
AU - Silani, Vincenzo
AU - Clark, Tara
AU - Arellano, Manuel
AU - Bos, Marjolein
AU - Kooy, Caroline
AU - Cabrera, Antonio
AU - Daniels-Scharbatke, Horst
AU - Azim Aburas, Kateřina
AU - Sofocleous, Christalena
AU - Sibón Sancho, Guillermo Manuel
AU - Travessa, André
AU - Ferreira, Ana Cristina
AU - Calzada, Yolanda
AU - Little, Mark A.
AU - Anne-Sophie, Lapointe
AU - Õunap, Katrin
AU - Sandgren, Katarina
AU - Gloudemans, dirk jan
AU - Bogdanova-Mihaylova, Petya
AU - Giffney, Claire
AU - Kotnik, Primož
AU - Ehrminger, Liis
AU - Tael, Kristi
AU - de Carmo Campos, Ana
AU - Nicole, Heider
AU - Aude, Servais
AU - Groselj, Urh
AU - Dan, Dorica
AU - McBrien, Jacqueline
AU - de Montalembert, Mariane
AU - Guillaume, Jondeau
AU - Kelleher, Suzanne
AU - Mykhailova, Tetiana
AU - Petersen, Birgit
AU - Grinfelde, Ieva
AU - Palamouti, Vasiliki
AU - Butenko, Tita
AU - Magalhães, Margarida
AU - Bouts, Antonia
AU - Fasano, Salvatore
AU - van der Beek, Nadine
N1 - Publisher Copyright:
© 2026 The Authors.
PY - 2026/9
Y1 - 2026/9
N2 - Background:Rare disease care pathways are complex and require coordination among specialised and non-specialised services, including genetic diagnostics, multidisciplinary expertise, and cross-border collaboration. Despite increasing policy attention and the establishment of European Reference Networks, the development and implementation of cohesive rare disease care pathways remain inconsistent across Europe. A shared, consensus-based framework reflecting stakeholder priorities is needed. Methods:This exploratory study combined structured stakeholder workshops and a Delphi consensus process. Nine workshops were conducted within the JARDIN project, engaging stakeholders from 16 European countries. Data were collected using standardised Miro boards and analysed thematically using MAXQDA, guided by the SEIPS 2.0 framework. Insights from this analysis informed the development of statements, which were evaluated through a Delphi survey. Consensus was predefined as a median score of at least 4, an interquartile range (IQR) ≤1, and ≥80% agreement (ratings 4–5). Results:A total of 216 individuals participated in the workshops, of whom 164 contributed during live sessions. Workshop data generated 1767 entries mapped across SEIPS domains. Seven thematic areas were identified: national strategy and governance; financing and sustainability; organisational structures and care coordination; access and equity; digital infrastructure and data systems; capacity building and education; and patient empowerment. Eighty-eight participants completed the Delphi survey, and consensus was achieved on all statements in the first round. Conclusion:The findings demonstrate strong cross-country agreement on system-level requirements for effective rare disease care pathways. These consensus statements provide a structured framework for developing national care pathways and integrating European Reference Networks activities into routine healthcare systems.
AB - Background:Rare disease care pathways are complex and require coordination among specialised and non-specialised services, including genetic diagnostics, multidisciplinary expertise, and cross-border collaboration. Despite increasing policy attention and the establishment of European Reference Networks, the development and implementation of cohesive rare disease care pathways remain inconsistent across Europe. A shared, consensus-based framework reflecting stakeholder priorities is needed. Methods:This exploratory study combined structured stakeholder workshops and a Delphi consensus process. Nine workshops were conducted within the JARDIN project, engaging stakeholders from 16 European countries. Data were collected using standardised Miro boards and analysed thematically using MAXQDA, guided by the SEIPS 2.0 framework. Insights from this analysis informed the development of statements, which were evaluated through a Delphi survey. Consensus was predefined as a median score of at least 4, an interquartile range (IQR) ≤1, and ≥80% agreement (ratings 4–5). Results:A total of 216 individuals participated in the workshops, of whom 164 contributed during live sessions. Workshop data generated 1767 entries mapped across SEIPS domains. Seven thematic areas were identified: national strategy and governance; financing and sustainability; organisational structures and care coordination; access and equity; digital infrastructure and data systems; capacity building and education; and patient empowerment. Eighty-eight participants completed the Delphi survey, and consensus was achieved on all statements in the first round. Conclusion:The findings demonstrate strong cross-country agreement on system-level requirements for effective rare disease care pathways. These consensus statements provide a structured framework for developing national care pathways and integrating European Reference Networks activities into routine healthcare systems.
UR - https://www.scopus.com/pages/publications/105050246896
U2 - 10.1016/j.ejmg.2026.105096
DO - 10.1016/j.ejmg.2026.105096
M3 - Article
C2 - 42562107
AN - SCOPUS:105050246896
SN - 1769-7212
VL - 83
JO - European Journal of Medical Genetics
JF - European Journal of Medical Genetics
M1 - 105096
ER -